# High Dose IL 2 and Entinostat in RCC

> **NCT03501381** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Roberto Pili** · enrollment: 46 (estimated)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Entinostat
- **DRUG:** Interleukin-2

## Key facts

- **NCT ID:** NCT03501381
- **Lead sponsor:** Roberto Pili
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-24
- **Primary completion:** 2023-01-20
- **Final completion:** 2024-04
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2023-09-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03501381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03501381, "High Dose IL 2 and Entinostat in RCC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03501381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*